Commercial Insight - Insomnia Strong brand identity critical to differentiation in an increasingly crowded mar Market-Report/Commercial-Ins ..Introduction Ambien has remained the clear leader in the insomnia market for over a decade, with 2006 sales of over $2.3 billion across the seven major markets.
The success of Ambien is...
Vanda Sleep Drug Data Sedate Investors Vanda Pharmaceuticals VNDA announced positive top-line results Thursday from a late-stage study on insomnia drug tasimelte, but the data may not prove compelling enough to rouse potential partners.Investors, skeptical about the phase III...
Vanda Sleep Drug Data Sedate Investors Vanda Pharmaceuticals VNDA announced positive top-line results Thursday from a late-stage study on insomnia drug tasimelte, but the data may not prove compelling enough to rouse potential partners.Investors, skeptical about the phase III...
Solutions For Sleeplessness The People's Pharmacy with Joe and Terry Graedon www.PeoplesPharmacy.com Newspaper Columns, Pharmacy Q&A June 11, 2008 Q.My wife has a sleeping problem and so do I.
She goes to bed and falls asleep about 10 pm, but wakes up around 2...
Sanofi-aventis reports positive results from depression study Total sleep time was increased in the Ambien CR group throughout the study.At week eight, patients reporting sleeping an average of 101 minutes more than baseline compared to placebo-treated patients who reported sleeping an average...
Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patie Ambien CR(R) 12.5 mg significantly improved sleep onset, sleep maintenance and total sleep time compared to placebo BRIDGEWATER, N.J., June 10 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today results from a new study that...
InvestSource Inc.: Global Entertainment Announces Major Deal to Produce 'Screwballs' Sequel (M2 PRESSWIRE via COMTEX) -- PAY | Quote | Chart | News | PowerRating -- Stocks in the News: Entertainment Acquisition Corporation (Other OTC: PSRZ), Precision Drilling Trust (NYSE: PDS), SkyWest, Inc.(NASDAQ: SKYW), General Mills (NYSE:...
Sanofi-Aventis Reports Positive Results From Depression Study Sanofi-aventis has announced positive results from a new study that showed Ambien CR CIV tablets 12.5mg provided significant improvement in sleep onset, sleep maintenance and total sleep time over eight weeks in patients with co-morbid...
Intermezzo(R) 3.5 mg Achieves Greater Early Bioavailability Than Ambien(R) 10 mg Despite 65% Lower Dose Data Presented as Poster Presentation at the Associated Professional Sleep Societies 2008 Annual Meeting BALTIMORE, June 11 /PRNewswire/ -- Data was presented today at the 22nd Annual Meeting of the Associated Professional Sleep Societies ...
Intermezzo 3.5 mg Achieves Greater Early Bioavailability Than Ambien 10 mg Despite 65% Lower Dose Data Presented as Poster Presentation at the Associated Professional Sleep Societies 2008 Annual Meeting BALTIMORE, June 11, 2008 /PRNewswire/ -- Data was presented today at the 22nd Annual Meeting of the Associated Professional Sleep...
Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patie Ambien CR(R) 12.5 mg significantly improved sleep onset, sleep maintenance and total sleep time compared to placebo BRIDGEWATER, N.J., June 10 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today results from a new study that...
Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved BRIDGEWATER, N.J., June 10 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today results from a new study that showed Ambien CR(R) (zolpidem tartrate extended-release) CIV tablets 12.5 mg provided significant improvement in sleep...
Ambien CR (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients Ambien CR(R) 12.5 mg significantly improved sleep onset, sleep maintenance and total sleep time compared to placebo BRIDGEWATER, N.J., June 10, 2008 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today results from a new study that...
New study shows Sanofi's Ambien CR improved sleep onset for insomnia patients PARIS (Thomson Financial) - Sanofi-Aventis (News/Aktienkurs) said a new study showed its Ambien CR tablets 'provided significant improvement in sleep onset, sleep maintenance and total sleep time over 8 weeks in patients with co-morbid...
New study shows Sanofi's Ambien CR improved sleep onset for insomnia patients PARIS (Thomson Financial) - Sanofi-Aventis said a new study showed its Ambien CR tablets 'provided significant improvement in sleep onset, sleep maintenance and total sleep time over 8 weeks in patients with co-morbid insomnia and...
New study shows Sanofi's Ambien CR improved sleep onset for insomnia patients PARIS (Thomson Financial) - Sanofi-Aventis said a new study showed its Ambien CR tablets 'provided significant improvement in sleep onset, sleep maintenance and total sleep time over 8 weeks in patients with co-morbid insomnia and...
New study shows Sanofi's Ambien CR improved sleep onset for insomnia patients PARIS (Thomson Financial) - Sanofi-Aventis said a new study showed its Ambien CR tablets 'provided significant improvement in sleep onset, sleep maintenance and total sleep time over 8 weeks in patients with co-morbid insomnia and...
Ambien CR (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients Ambien CR(R) 12.5 mg significantly improved sleep onset, sleep maintenance and total sleep time compared to placebo BRIDGEWATER, N.J., June 10, 2008 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today results from a new study that...
Antidepressants Linked to Preterm Birth (Washington) -- Taking antidepressants in pregnancy may raise the risk of giving birth prematurely, researchers report.But left untreated, depression may also increase the chance of preterm birth, says researcher Katherine Wisner, MD,...
OUTLOOK Sanofi Aventis seen reporting drop in Q1 EPS as dollar, generics weigh PARIS (Thomson Financial) - Sanofi Aventis is expected to post on Wednesday morning a slight decline in earnings per share for the first quarter as the weakening U.S.dollar and the impact of competition from generic drugs weigh on the...
Neurogen to raise $30.6m for research programmes though private placement In an effort to focus resources on its four clinical trials programmes, Neurogen Corporation has unveiled plans to raise $30.6 million in a private placement and cut 45 workers.The decision came as part of the company's plan to focus...
